Skip to main content
. 2022 Apr 15;9:821776. doi: 10.3389/fmed.2022.821776

Figure 1.

Figure 1

Concordance between various estimates of sputum bacterial load and clinical assessment of disease severity across TB patients at time of diagnosis and after 5 months of antibiotic treatment. (A) Evolution of clinical TB score after 5 months of anti-tuberculous treatment (Month 5 ATT) (Wilcoxon matched-pairs signed rank test p-value). Sputum molecular bacterial load assay (MBLA) results from specimens before initiation of anti-tuberculous treatment (ATT) against: (B) Xpert MTB/RIF Ct values from an independent sputum specimen or (C) time to culture positivity in weeks, or (D) solid culture intensity grades from the same sputum specimen and (E) patient's clinical TB score at time of diagnosis. Xpert MTB/RIF Ct values from sputum specimens before initiation of anti-tuberculous treatment (ATT) against: (F) time to culture positivity results from an independent sputum specimen or (G) solid culture intensity grades from an independent sputum specimen, or (H) patient's clinical TB score at time of diagnosis. (I) Time to culture positivity results against solid culture intensity grades from the same sputum specimen. Patient's clinical TB score at time of diagnosis against (J) sputum solid culture intensity grades or (K) time to culture positivity results. (B) Pearson correlation p-value (two-tailed) and R squared. (C–K) Ordinary one-way ANOVA test for trend p-values with slopes for p < 0.05.